

# Marcos Gonzalez DÃ-az

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/783388/publications.pdf>

Version: 2024-02-01

230  
papers

20,570  
citations

20797

60  
h-index

11047

137  
g-index

233  
all docs

233  
docs citations

233  
times ranked

22082  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. <i>Leukemia</i> , 2003, 17, 2257-2317.	3.3	2,788
2	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	13.7	2,114
3	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2011, 475, 101-105.	13.7	1,364
4	Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia " A Europe Against Cancer Program. <i>Leukemia</i> , 2003, 17, 2318-2357.	3.3	1,359
5	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2012, 44, 47-52.	9.4	893
6	Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature</i> , 2015, 526, 519-524.	13.7	749
7	Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. <i>Leukemia</i> , 2017, 31, 2094-2103.	3.3	486
8	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monotherapy: a multicenter study by the PETHEMA group. <i>Blood</i> , 2003, 103, 1237-1243.	0.6	395
9	Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. <i>Blood</i> , 2014, 123, 3073-3079.	0.6	380
10	Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. <i>Blood</i> , 2001, 98, 1746-1751.	0.6	316
11	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. <i>Blood</i> , 2008, 111, 3395-3402.	0.6	303
12	Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. <i>Blood</i> , 2009, 113, 775-783.	0.6	279
13	Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. <i>Annals of Oncology</i> , 1998, 9, 849-855.	0.6	264
14	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 2122-2130.	0.6	260
15	MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. <i>Leukemia</i> , 2013, 27, 1722-1728.	3.3	238
16	Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. <i>Blood</i> , 2008, 112, 2709-2712.	0.6	213
17	Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. <i>Leukemia</i> , 2010, 24, 629-637.	3.3	188
18	Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. <i>Blood</i> , 2009, 114, 33-37.	0.6	183

#	ARTICLE	IF	CITATIONS
19	NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. <i>Leukemia</i> , 2013, 27, 1100-1106.	3.3	167
20	Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. <i>Haematologica</i> , 2010, 95, 87-95.	1.7	164
21	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. <i>Blood</i> , 2007, 110, 3112-3121.	0.6	157
22	Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. <i>Leukemia</i> , 2014, 28, 391-397.	3.3	155
23	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. <i>Blood</i> , 2008, 112, 3130-3134.	0.6	154
24	Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. <i>Haematologica</i> , 2005, 90, 1365-72.	1.7	135
25	A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. <i>Leukemia</i> , 2015, 29, 598-605.	3.3	129
26	Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 7632-7640.	0.8	126
27	Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. <i>Leukemia</i> , 2007, 21, 446-452.	3.3	124
28	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. <i>Blood</i> , 2003, 101, 4042-4046.	0.6	121
29	Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. <i>Clinical Cancer Research</i> , 2008, 14, 155-161.	3.2	117
30	Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 4578-4584.	0.8	116
31	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. <i>Blood</i> , 2011, 117, 1799-1805.	0.6	112
32	Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. <i>British Journal of Haematology</i> , 1986, 64, 547-560.	1.2	108
33	TCR $\beta$ <sup>+</sup> /CD4 <sup>+</sup> Large Granular Lymphocytosis. <i>American Journal of Pathology</i> , 2003, 163, 763-771.	1.9	104
34	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. <i>Blood</i> , 2007, 109, 4258-4263.	0.6	104
35	Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. <i>Leukemia</i> , 2002, 16, 1423-1431.	3.3	103
36	Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. <i>Blood</i> , 2003, 102, 2994-3002.	0.6	101

#	ARTICLE	IF	CITATIONS
37	SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status. <i>Leukemia</i> , 2012, 26, 2521-2529.	3.3	100
38	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014, 123, 3790-3796.	0.6	97
39	Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expression. <i>Leukemia</i> , 2001, 15, 406-414.	3.3	94
40	Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. <i>Haematologica</i> , 2009, 94, 1242-1249.	1.7	93
41	TCR $\beta$ <sup>hi</sup> + large granular lymphocyte leukemias reflect the spectrum of normal antigen-selected TCR $\beta$ <sup>hi</sup> + T-cells. <i>Leukemia</i> , 2006, 20, 505-513.	3.3	86
42	Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 402-409.	3.3	85
43	Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. <i>Haematologica</i> , 2010, 95, 424-431.	1.7	84
44	Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. <i>Haematologica</i> , 2012, 97, 1218-1224.	1.7	83
45	The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. <i>Leukemia</i> , 2012, 26, 1821-1828.	3.3	83
46	CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. <i>Blood</i> , 2007, 110, 461-467.	0.6	82
47	Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis. <i>British Journal of Haematology</i> , 2008, 142, 529-537.	1.2	78
48	Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2009, 114, 148-152.	0.6	78
49	Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. <i>British Journal of Haematology</i> , 2002, 118, 1034-1040.	1.2	76
50	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. <i>British Journal of Haematology</i> , 2007, 136, 590-596.	1.2	75
51	Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. <i>British Journal of Haematology</i> , 1995, 90, 106-112.	1.2	74
52	Characterization of aberrant phenotypes in acute myeloblastic leukemia. <i>Annals of Hematology</i> , 1995, 70, 189-194.	0.8	73
53	Expression of <i>MALT1</i> oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10534-10539.	3.3	73
54	Monoclonal TCR $\beta$ <sup>hi</sup> 13.1+/CD4+/NKa+/CD8 $\alpha$ <sup>hi</sup> /+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. <i>Blood</i> , 2007, 109, 4890-4898.	0.6	72

#	ARTICLE	IF	CITATIONS
55	<scp>CXCR4</scp> expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. <i>Journal of Pathology</i> , 2015, 235, 445-455.	2.1	71
56	Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. <i>PLoS ONE</i> , 2016, 11, e0146722.	1.1	70
57	Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. <i>British Journal of Haematology</i> , 1996, 93, 81-88.	1.2	69
58	A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. <i>Cytometry</i> , 1994, 17, 332-339.	1.8	68
59	Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. <i>Blood</i> , 2019, 134, 2218-2222.	0.6	66
60	Lymphoid subsets and prognostic factors in multiple myeloma. <i>British Journal of Haematology</i> , 1992, 80, 305-309.	1.2	64
61	Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. <i>Cancer Genetics</i> , 2013, 206, 49-62.	0.2	63
62	Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyt. <i>British Journal of Haematology</i> , 2001, 114, 931-936.	1.2	60
63	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 108.	2.8	60
64	A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. <i>Haematologica</i> , 2009, 94, 364-371.	1.7	59
65	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. <i>Haematologica</i> , 2011, 96, 1470-1477.	1.7	59
66	Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2007, 92, 635-642.	1.7	57
67	Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia. <i>Leukemia</i> , 2012, 26, 2360-2366.	3.3	55
68	Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 3951-3959.	0.6	55
69	3Immunophenotype and DNA cell content in multiple myeloma. <i>Best Practice and Research: Clinical Haematology</i> , 1995, 8, 735-759.	1.1	54
70	Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect. <i>British Journal of Haematology</i> , 2002, 118, 239-242.	1.2	54
71	Expanded cells in monoclonal TCR- $\hat{1}\pm\hat{1}^2+$ /CD4+/NKa+/CD8 $\hat{a}^+$ /+dim T-LGL lymphocytosis recognize hCMV antigens. <i>Blood</i> , 2008, 112, 4609-4616.	0.6	54
72	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , 2010, 95, 1317-1324.	1.7	53

#	ARTICLE	IF	CITATIONS
73	Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR $\alpha$ isoforms: a study of the PETHEMA group. <i>British Journal of Haematology</i> , 2001, 114, 99-103.	1.2	52
74	Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. <i>British Journal of Haematology</i> , 1986, 62, 75-83.	1.2	51
75	Prognostic factors and classification in multiple myeloma. <i>British Journal of Cancer</i> , 1989, 59, 113-118.	2.9	50
76	Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. <i>Leukemia</i> , 2001, 15, 840-845.	3.3	50
77	High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. <i>Leukemia Research</i> , 2009, 33, 1706-1709.	0.4	49
78	Long FLT3 internal tandem duplications and reduced PML-RAR $\alpha$ expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. <i>Haematologica</i> , 2010, 95, 745-751.	1.7	47
79	Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. <i>British Journal of Cancer</i> , 1993, 68, 1227-1231.	2.9	45
80	Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. <i>Leukemia</i> , 2007, 21, 1413-1422.	3.3	45
81	Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders. <i>Haemophilia</i> , 2016, 22, 590-597.	1.0	43
82	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. <i>Nature Communications</i> , 2016, 7, 11889.	5.8	42
83	Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. <i>Blood Advances</i> , 2022, 6, 774-784.	2.5	42
84	The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. <i>Haematologica</i> , 2008, 93, 1797-1805.	1.7	41
85	Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease "a study within the Europe Against Cancer Program. <i>Leukemia</i> , 2004, 18, 884-886.	3.3	40
86	BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). <i>Annals of Hematology</i> , 2010, 89, 453-458.	0.8	40
87	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 576-586.	1.7	40
88	Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1830-1842.	0.6	40
89	Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. <i>British Journal of Haematology</i> , 2012, 157, 67-74.	1.2	39
90	Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications. <i>Leukemia</i> , 2003, 17, 1398-1403.	3.3	38

#	ARTICLE	IF	CITATIONS
91	Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 83.	6.9	38
92	FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. <i>The Hematology Journal</i> , 2004, 5, 239-246.	2.0	37
93	Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14. <i>PLoS ONE</i> , 2012, 7, e48485.	1.1	37
94	Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. <i>Thrombosis and Haemostasis</i> , 2017, 117, 66-74.	1.8	36
95	Lymphoid subsets in acute myeloid leukemias: Increased number of cells with NK phenotype and normal T-cell distribution. <i>Annals of Hematology</i> , 1993, 67, 217-222.	0.8	35
96	Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. <i>Haematologica</i> , 2018, 103, 1198-1208.	1.7	34
97	Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. <i>British Journal of Haematology</i> , 1991, 79, 408-414.	1.2	33
98	Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. <i>Blood</i> , 2010, 116, 5650-5659.	0.6	33
99	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. <i>Haematologica</i> , 2014, 99, e231-e234.	1.7	33
100	Common Infectious Agents and Monoclonal B-Cell Lymphocytosis: A Cross-Sectional Epidemiological Study among Healthy Adults. <i>PLoS ONE</i> , 2012, 7, e52808.	1.1	32
101	Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. <i>Cancer</i> , 2009, 115, 3728-3737.	2.0	31
102	Molecular Characterization of Immunoglobulin Gene Rearrangements in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2012, 181, 1879-1888.	1.9	31
103	Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2358-2370.	3.3	31
104	p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. <i>The Hematology Journal</i> , 2001, 2, 146-149.	2.0	30
105	Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. <i>Leukemia</i> , 2007, 21, 1481-1487.	3.3	29
106	Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 212-215.	1.2	29
107	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. <i>Haematologica</i> , 2011, 96, 468-471.	1.7	29
108	Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. <i>Oncotarget</i> , 2016, 7, 80916-80924.	0.8	29



#	ARTICLE	IF	CITATIONS
109	Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. <i>Leukemia Research</i> , 2016, 40, 1-9.	0.4	29
110	B-cell chronic lymphocytic leukaemia: Prognostic value of the immunophenotype and the clinico-haematological features. <i>American Journal of Hematology</i> , 1989, 31, 26-31.	2.0	28
111	Detection of MYD88 L265P Mutation by Real-Time Allele-Specific Oligonucleotide Polymerase Chain Reaction. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 768-773.	0.6	28
112	The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 1144-1152.	0.6	28
113	Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR. <i>Leukemia</i> , 2003, 17, 1051-1057.	3.3	27
114	Combined Patterns of IGHV Repertoire and Cytogenetic/Molecular Alterations in Monoclonal B Lymphocytosis versus Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2013, 8, e67751.	1.1	27
115	Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study. <i>Haematologica</i> , 2015, 100, 1294-1300.	1.7	27
116	A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2016, 34, 84-92.	0.8	26
117	Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population. <i>British Journal of Haematology</i> , 2019, 185, 480-491.	1.2	26
118	Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2006, 135, 43-51.	1.2	25
119	A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. <i>Blood Advances</i> , 2018, 2, 1719-1737.	2.5	25
120	T-cell subpopulations in patients with monoclonal gammopathies: Essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia. <i>American Journal of Hematology</i> , 1985, 20, 267-273.	2.0	24
121	Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. <i>British Journal of Haematology</i> , 1995, 89, 104-109.	1.2	24
122	Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. <i>Cytometry</i> , 1995, 22, 217-222.	1.8	24
123	Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. <i>British Journal of Haematology</i> , 2002, 117, 890-892.	1.2	24
124	A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0143073.	1.1	24
125	Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia. <i>Journal of Pathology</i> , 2018, 245, 61-73.	2.1	24
126	Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 135, 2375-2387.	0.6	24



#	ARTICLE	IF	CITATIONS
127	HLA-DPB1 MISMATCH IN HLA-A-B-DRB1 IDENTICAL SIBLING DONOR STEM CELL TRANSPLANTATION AND ACUTE GRAFT-VERSUS-HOST DISEASE. <i>Transplantation</i> , 2004, 77, 1107-1110.	0.5	23
128	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 122, 1448-1454.	0.6	23
129	Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2014, 99, 155-162.	1.7	23
130	Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 668-680.	1.5	23
131	Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study. <i>British Journal of Haematology</i> , 1992, 82, 671-675.	1.2	22
132	Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. <i>Blood</i> , 2008, 111, 5130-5141.	0.6	22
133	Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. <i>Annals of Hematology</i> , 2013, 92, 1151-1179.	0.8	22
134	Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders. <i>Haematologica</i> , 2014, 99, 897-907.	1.7	22
135	Mapping of Genetic Abnormalities of Primary Tumours from Metastatic CRC by High-Resolution SNP Arrays. <i>PLoS ONE</i> , 2010, 5, e13752.	1.1	22
136	Combination of interferon and dexamethasone in refractory multiple myeloma. <i>Hematological Oncology</i> , 1990, 8, 185-189.	0.8	20
137	Immunoglobulin lambda isotype gene rearrangements in B cell malignancies. <i>Leukemia</i> , 2001, 15, 121-127.	3.3	20
138	Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). <i>Leukemia and Lymphoma</i> , 2014, 55, 1007-1012.	0.6	20
139	CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e183-e185.	1.7	20
140	Molecular characteristics and gene segment usage in IGH gene rearrangements in multiple myeloma. <i>Haematologica</i> , 2005, 90, 906-13.	1.7	20
141	Two new 3?PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. , 2000, 27, 35-43.		19
142	High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016, 95, 253-262.	0.8	19
143	Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia. <i>Leukemia</i> , 2018, 32, 2701-2705.	3.3	19
144	Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols.. <i>Blood</i> , 2006, 108, 1503-1503.	0.6	19

#	ARTICLE	IF	CITATIONS
145	Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis. PLoS ONE, 2017, 12, e0182470.	1.1	19
146	Allogeneic peripheral stem cell transplantation in a case of hereditary sideroblastic anaemia. British Journal of Haematology, 2000, 109, 658-660.	1.2	18
147	Functional class switch recombination may occur "in vivo" in Waldenström macroglobulinaemia. British Journal of Haematology, 2007, 136, 114-116.	1.2	18
148	The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. Annals of Hematology, 2013, 92, 97-100.	0.8	18
149	Discrepancies Between Morphologic, Cytochemical, and Immunologic Characteristics in Acute Myeloblastic Leukemia. American Journal of Clinical Pathology, 1987, 88, 38-42.	0.4	17
150	The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. Leukemia, 2015, 29, 1435-1437.	3.3	17
151	Origin of Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 136-147.	0.7	17
152	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer, 2015, 15, 238.	1.1	16
153	Immunoblastic lymphoma and associated non-lymphoid malignancies following two cases of Waldenström's macroglobulinemia. A review of the literature. European Journal of Haematology, 1993, 50, 299-301.	1.1	15
154	Multipronged functional proteomics approaches for global identification of altered cell signalling pathways in B-cell chronic lymphocytic leukaemia. Proteomics, 2016, 16, 1193-1203.	1.3	15
155	Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 2001, 28, 665-672.	1.3	14
156	Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain). Tissue Antigens, 2011, 78, 249-255.	1.0	14
157	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping. British Journal of Haematology, 2021, 195, 542-551.	1.2	14
158	MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. International Journal of Molecular Sciences, 2022, 23, 5570.	1.8	14
159	TdT activity in acute myeloid leukemias defined by monoclonal antibodies. American Journal of Hematology, 1986, 23, 9-17.	2.0	13
160	Clinical and immunological findings in large B-cell chronic lymphocytic leukemia. Clinical Immunology and Immunopathology, 1988, 46, 177-185.	2.1	13
161	Immunological features of sporadic multinodular goiter. The Clinical Investigator, 1993, 71, 552-8.	0.6	13
162	Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling. Annals of Oncology, 2012, 23, 2138-2146.	0.6	13

#	ARTICLE	IF	CITATIONS
163	Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2042-2047.	2.0	13
164	Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas. <i>British Journal of Haematology</i> , 2002, 119, 883-884.	1.2	12
165	Molecular and Epidemiologic Findings of Childhood Acute Leukemia in Costa Rica. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 131-135.	0.3	12
166	TET2 Overexpression in Chronic Lymphocytic Leukemia Is Unrelated to the Presence of TET2 Variations. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	12
167	Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles. <i>Leukemia Research</i> , 2015, 39, 921-924.	0.4	12
168	Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2020, 189, 718-730.	1.2	12
169	Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. <i>Laboratory Investigation</i> , 2008, 88, 306-317.	1.7	11
170	Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2014, 38, 551-556.	0.4	11
171	The Genotype of the Donor for the (GT) <sub>n</sub> Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2015, 10, e0140454.	1.1	11
172	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. <i>Blood Cancer Journal</i> , 2019, 9, 52.	2.8	11
173	Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia. <i>Molecular Cancer</i> , 2022, 21, 35.	7.9	11
174	The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma. <i>Haematologica</i> , 2006, 91, 1551-4.	1.7	11
175	Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 1997, 74, 79-82.	0.8	10
176	Multiple cranial neuropathy and intracranial hypertension associated with all-trans retinoic acid treatment in a young adult patient with acute promyelocytic leukemia. <i>International Journal of Hematology</i> , 2012, 96, 383-385.	0.7	10
177	Pediatric Primary Follicular Mucinosis: Further Evidence of its Relationship with Mycosis Fungoides. <i>Pediatric Dermatology</i> , 2013, 30, e218-20.	0.5	10
178	Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-cell Lymphoma. <i>Cancers</i> , 2020, 12, 474.	1.7	10
179	Molecular Characterization of Complete and Incomplete Immunoglobulin Heavy Chain Gene Rearrangements in Hairy Cell Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 573-579.	1.4	9
180	Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: implications for disease progression. <i>Haematologica</i> , 2017, 102, 1238-1246.	1.7	9

#	ARTICLE	IF	CITATIONS
181	Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy. <i>Modern Pathology</i> , 2018, 31, 1318-1331.	2.9	9
182	Acute lymphoid leukemias following either a previous chronic myelogenous leukemia or myelodysplastic syndrome: Phenotypic and genomic differences. <i>American Journal of Hematology</i> , 1993, 43, 256-258.	2.0	8
183	Quantitative Assessment of PML-RARa and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional Laboratory Trial. <i>Clinical Chemistry</i> , 2004, 50, 1088-1092.	1.5	8
184	MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion. <i>Leukemia Research</i> , 2016, 46, 30-36.	0.4	8
185	Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 633-642.	0.6	8
186	Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 436.	1.7	8
187	A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2018, 9, 26019-26031.	0.8	8
188	The value of the immunological subtypes and individual markers compared to classical parameters in the prognosis of acute lymphoblastic leukemia. <i>Hematological Oncology</i> , 2006, 9, 33-42.	0.8	7
189	Hyperhomocysteinemia is a risk factor of recurrent coronary event in young patients irrespective to the MTHFR C677T polymorphism. <i>Thrombosis Research</i> , 2007, 119, 691-698.	0.8	7
190	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 163, 223-234.	1.2	7
191	Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis. <i>Cell Cycle</i> , 2014, 13, 1717-1726.	1.3	7
192	Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities?. <i>Annals of Hematology</i> , 2015, 94, 609-616.	0.8	7
193	Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 862-871.	1.2	7
194	HELPER/SUPPRESSOR T-CELL SUBPOPULATIONS IN BENIGN PARAPROTEINAEMIA. <i>British Journal of Haematology</i> , 1983, 54, 318-320.	1.2	6
195	Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. <i>Leukemia and Lymphoma</i> , 2009, 50, 1283-1289.	0.6	6
196	Molecular and flow cytometry characterization during the follow-up of three simultaneous lymphoproliferative disorders: Hairy cell leukemia, monoclonal B-cell lymphocytosis, and CD4 <sup>++</sup> /CD8 <sup>+</sup> dim T-large granular lymphocytosis. A case report. <i>Cytometry Part B - Clinical Cytometry</i> , 2011, 80B, 195-200.	0.7	6
197	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. <i>European Journal of Haematology</i> , 2020, 104, 162-169.	1.1	6
198	Status of methylation of p16 gene in multiple myeloma: a comparative study of three methods for its detection. <i>Clinical Biochemistry</i> , 2000, 33, 415-418.	0.8	5

#	ARTICLE	IF	CITATIONS
199	Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia. <i>Leukemia Research</i> , 2009, 33, e20-e22.	0.4	5
200	Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation. <i>European Journal of Haematology</i> , 2012, 89, 250-255.	1.1	5
201	Subjects with chronic lymphocytic leukaemia like B-cell clones with stereotyped B-cell receptors frequently show MDS-associated phenotypes on myeloid cells. <i>British Journal of Haematology</i> , 2015, 168, 258-267.	1.2	5
202	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 2318-2326.	0.6	5
203	Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols. <i>Blood</i> , 2004, 104, 2019-2019.	0.6	5
204	CYTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF MONOCLONAL GAMMOPATHIES. <i>British Journal of Haematology</i> , 1985, 60, 768-769.	1.2	4
205	PLASMBLASTIC MULTIPLE MYELOMA: AN IMMUNOLOGICALLY DIFFERENT SUBTYPE. <i>British Journal of Haematology</i> , 1987, 66, 275-281.	1.2	4
206	Bone marrow histopathologic patterns and immunologic phenotype in B-cell chronic lymphocytic leukaemia. <i>Blut</i> , 1988, 57, 19-23.	1.2	4
207	Clinical and Prognostic Value of Discrepancies in Microsatellite DNA Regions Between Recipient and Donor in Human Leukocyte Antigen-Identical Allogeneic Transplantation Setting. <i>Transplantation</i> , 2008, 86, 983-990.	0.5	4
208	Coexpression of T and B markers in a lymphoproliferative disorder. <i>Scandinavian Journal of Haematology</i> , 1986, 37, 10-17.	0.0	4
209	Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis. <i>Hematology Reports</i> , 2014, 6, 5654.	0.3	4
210	HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. <i>PLoS ONE</i> , 2017, 12, e0172978.	1.1	4
211	Letter to the editor: T-cell subsets and myeloma cell mass. <i>American Journal of Hematology</i> , 1987, 25, 235-236.	2.0	3
212	Skin involvement in non-secretory myeloma. <i>American Journal of Medicine</i> , 1988, 84, 373-374.	0.6	3
213	Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1991, 27, S48-S49.	0.9	3
214	The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML. <i>Annals of Hematology</i> , 1994, 68, 233-236.	0.8	3
215	The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease. <i>Tissue Antigens</i> , 2008, 71, 548-551.	1.0	3
216	Genetic complexity impacts the clinical outcome of follicular lymphoma patients. <i>Blood Cancer Journal</i> , 2021, 11, 11.	2.8	3

#	ARTICLE	IF	CITATIONS
217	Two new PML Breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2000, 27, 35-43.	1.5	3
218	Actualización de las guías nacionales de consenso del Grupo Español de Leucemia Linfocítica Crónica para el tratamiento y seguimiento de la leucemia linfocítica crónica. <i>Medicina Clínica</i> , 2017, 148, 381.e1-381.e9.	0.3	2
219	Exportin1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma. <i>Hematological Oncology</i> , 2019, 37, 215-218.	0.8	2
220	Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. <i>Annals of Hematology</i> , 2021, 100, 825-830.	0.8	2
221	Acute leukemia of hybrid phenotype: T lymphoid and myelomonocytic markers. <i>Clinical Immunology and Immunopathology</i> , 1985, 35, 139-145.	2.1	1
222	Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2011, 90, 227-229.	0.8	1
223	Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT. <i>Bone Marrow Transplantation</i> , 2015, 50, 298-300.	1.3	1
224	Allele and haplotype frequencies of HLA-A, -B, -C, -DRB1, -DQB1 and -DQA1 in Castile and Leon region from North West of Spain. <i>Human Immunology</i> , 2021, 82, 549-550.	1.2	1
225	Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM). <i>PLoS ONE</i> , 2021, 16, e0257353.	1.1	1
226	The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival. <i>Blood</i> , 2016, 128, 375-375.	0.6	1
227	Expression of the FMC7 antigen in cases of B-lymphoproliferative diseases. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1987, 23, 1417-1418.	0.9	0
228	Sarcoma histiocítico en intestino delgado: estudio y discusión de un caso con reordenamiento clonal linfocitario B. <i>Revista Española De Patología</i> , 2016, 49, 254-258.	0.6	0
229	The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. <i>Frontiers in Oncology</i> , 2021, 11, 723722.	1.3	0
230	Identification and Characterization of Single Nucleotide Polymorphisms (SNPs) Associated with Genetic Predisposition to Develop Therapy-Related Acute Myeloid Leukemia (t-AML).. <i>Blood</i> , 2004, 104, 3001-3001.	0.6	0